# Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD

> **NCT00032773** · PHASE1,PHASE2 · TERMINATED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 36 (—)

## Conditions studied

- Acute Graft Versus Host Disease

## Interventions

- **DRUG:** pentostatin for injection

## Key facts

- **NCT ID:** NCT00032773
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-01-30
- **Primary completion:** 2005-11-03
- **Final completion:** 2005-11-03
- **Target enrollment:** 36 (—)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00032773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00032773, "Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00032773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*